iSpecimen holders approve dilutive financings and Foldlab AI asset deal; reverse-split vote adjourned to Oct 30

iSpecimen Inc.

Special meeting held Oct 9, 2026 drew 1,287,547 shares (51.1%) of 2,518,590 outstanding, constituting a quorum.
Proposal 2, a reverse split of 1:10 to 1:100 at the board's discretion, was adjourned to Oct 30, 2026 at 10:00 a.m. ET; record date remains Aug 12, 2026 and prior proxies stay valid.
Stockholders approved Nasdaq Rule 5635(d) issuance of shares underlying Pre-Funded Warrants from the May 8, 2026 Securities Purchase Agreement; vote was 779,705 for, 33,092 against.
Proposal 3 approved 782,722 to 30,099: future convertible/equity-linked financings over 12 months at discounts up to 80% off the lowest VWAP, including warrants, resets and MFN rights.
Proposal 4 approved 791,600 to 21,269 for the asset acquisition from Foldlab AI Ltd. under the Sept 4, 2026 Asset Purchase Agreement, partly payable in common stock.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.